BRIEF-Living Cell Technologies Secures Funding For Third Clinical Trial Of NTCELL In Parkinson's Disease
BRIEF-Living Cell Technologies Secures Funding For Third Clinical Trial Of NTCELL In Parkinson's Disease
Brief-Living Cell Technologies为NTCELL治疗帕金森病的第三次临床试验获得资金
Oct 19 (Reuters) - Living Cell Technologies Ltd LCT.AX :
路透10月19日电-Living Cell Technologies Ltd LCT.AX：
* SECURED FUNDING FOR A THIRD CLINICAL TRIAL OF NTCELL IN PARKINSON'S DISEASE
*获得资金，用于NTCELL在帕金森病中的第三次临床试验
* COMPLETED PLACEMENT RAISING A$3.5 MILLION
*完成配售，筹集350万澳元
Source text for Eikon: ID:nASXbgXbmM Further company coverage: LCT.AX
Eikon的源文本：ID：nASXbgXbmM进一步的公司报道：LCT.AX
((Reuters.Briefs@thomsonreuters.com;))
(Reurs.Briefs@thomsonreurs.com；)